Drug Profile
Research programme: neurokinin receptor antagonists - sanofi-aventis
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class Small molecules
- Mechanism of Action Neurokinin 2 antagonists; Neurokinin 3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Irritable bowel syndrome; Major depressive disorder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Irritable-bowel-syndrome in France
- 04 Nov 2017 No recent reports of development identified for preclinical development in Major depressive disorder in France
- 08 Mar 2007 Preclinical development is ongoing for depression, irritable bowel syndrome, schizophrenia and anxiety